Precision Medicine Online

AstraZeneca's Truqap Gets FDA Advisory Committee Backing in PTEN-Deficient Advanced ...

The ODAC voted seven-to-one that data from the CAPItello-281 trial showed a favorable benefit-risk profile for Truqap plus abiraterone and ADT.